Robert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) COO Robert Ticktin sold 23,151 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $24,540.06. Following the transaction, the chief operating officer directly owned 98,695 shares in the company, valued at $104,616.70. The trade was a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

PMV Pharmaceuticals Price Performance

PMVP stock traded up $0.11 on Friday, hitting $1.21. 582,828 shares of the company were exchanged, compared to its average volume of 197,220. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82. The business's fifty day moving average is $0.99 and its two-hundred day moving average is $1.18. The stock has a market capitalization of $62.86 million, a price-to-earnings ratio of -1.03 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. Equities research analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

Institutional Investors Weigh In On PMV Pharmaceuticals

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in shares of PMV Pharmaceuticals by 2,282.8% in the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock valued at $37,000 after purchasing an additional 23,559 shares during the period. Velan Capital Investment Management LP purchased a new position in shares of PMV Pharmaceuticals in the fourth quarter valued at $53,000. Squarepoint Ops LLC boosted its stake in PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock valued at $110,000 after acquiring an additional 29,722 shares during the last quarter. Northern Trust Corp grew its holdings in PMV Pharmaceuticals by 23.2% during the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after acquiring an additional 20,190 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in PMV Pharmaceuticals by 44.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock worth $305,000 after acquiring an additional 62,200 shares in the last quarter. Institutional investors and hedge funds own 90.20% of the company's stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.